Global Pediatric Vaccine Market 2019-2023
SKU ID :TNV-13142969 | Published Date: 14-Feb-2019 | No. of pages: 128Description
TOC
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Conjugate vaccines and others - Market size and forecast 2018-2023
• Live-attenuated vaccines - Market size and forecast 2018-2023
• Toxoid vaccines - Market size and forecast 2018-2023
• Inactivated vaccines - Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
• Monovalent vaccines
• Multivalent vaccines
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• CSL Limited
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi
PART 15: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Global vaccine market
Exhibit 02: Segments of global vaccine market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pediatric vaccines in the pipeline
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Conjugate vaccines and others - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Conjugate vaccines and others - Year-over-year growth 2019-2023 (%)
Exhibit 22: Sales of leading conjugate vaccines 2015-2017 ($ millions)
Exhibit 23: Live-attenuated vaccines - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Live-attenuated vaccines - Year-over-year growth 2019-2023 (%)
Exhibit 25: Sales of leading live-attenuated vaccines 2015-2017 ($ millions)
Exhibit 26: Toxoid vaccines - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Toxoid vaccines - Year-over-year growth 2019-2023 (%)
Exhibit 28: Inactivated vaccines - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Inactivated vaccines - Year-over-year growth 2019-2023 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Market share by geography 2018-2023 (%)
Exhibit 33: Geographic comparison
Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Incidence rates for malaria 2017 (reported by the World Bank)
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Immunization programs for children
Exhibit 46: Recently approved vaccines by the FDA
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: CSL Limited - Vendor overview
Exhibit 54: CSL Limited - Business segments
Exhibit 55: CSL Limited - Organizational developments
Exhibit 56: CSL Limited - Geographic focus
Exhibit 57: CSL Limited - Segment focus
Exhibit 58: CSL Limited - Key offerings
Exhibit 59: GlaxoSmithKline plc - Vendor overview
Exhibit 60: GlaxoSmithKline plc - Business segments
Exhibit 61: GlaxoSmithKline plc - Organizational developments
Exhibit 62: GlaxoSmithKline plc - Geographic focus
Exhibit 63: GlaxoSmithKline plc - Segment focus
Exhibit 64: GlaxoSmithKline plc - Key offerings
Exhibit 65: Merck & Co., Inc. - Vendor overview
Exhibit 66: Merck & Co., Inc. - Business segments
Exhibit 67: Merck & Co., Inc. - Organizational developments
Exhibit 68: Merck & Co., Inc. - Geographic focus
Exhibit 69: Merck & Co., Inc. - Segment focus
Exhibit 70: Merck & Co., Inc. - Key offerings
Exhibit 71: Pfizer Inc. - Vendor overview
Exhibit 72: Pfizer Inc. - Business segments
Exhibit 73: Pfizer Inc. - Organizational developments
Exhibit 74: Pfizer Inc. - Geographic focus
Exhibit 75: Pfizer Inc. - Segment focus
Exhibit 76: Pfizer Inc. - Key offerings
Exhibit 77: Sanofi - Vendor overview
Exhibit 78: Sanofi - Business segments
Exhibit 79: Sanofi - Organizational developments
Exhibit 80: Sanofi - Geographic focus
Exhibit 81: Sanofi - Segment focus
Exhibit 82: Sanofi - Key offerings
Exhibit 83: Validation techniques employed for market sizing
Tables & Figures
Companies
CSL Limited
GlaxoSmithKline plc
Merck & Co.
Inc.
Pfizer Inc.
and Sanofi
- PRICE
-
$2500$4000